Publications by authors named "Christopher Ryan Miller"
Article Synopsis
- Deletions or mutations in the PTEN gene are common in glioblastoma (GBM) and lead to issues with DNA damage repair; this study investigates whether PTEN deficiency creates a weakness against combined DNA damage and repair suppression using specific inhibitors.
- Researchers treated different GBM cell lines with the drug LMP400 (a TOP1 inhibitor) alone and with either PARP inhibitors (Olaparib or Niraparib) and found that PTEN-null cells are significantly more sensitive to this treatment.
- The combination of LMP400 and Niraparib not only increases cell death in PTEN-deficient glioma cells but also shows promise in animal models for penetrating the blood-brain barrier and improving survival, supporting the
Background: Glioblastoma-associated macrophages and microglia (GAMs) are the predominant immune cells in the tumor microenvironment. Activation of MerTK, a receptor tyrosine kinase, polarizes GAMs to an immunosuppressive phenotype, promoting tumor growth. Here, the role of MerTK inhibition in the glioblastoma microenvironment is investigated in vitro and in vivo.
View Article and Find Full Text PDFThe World Health Organization recently updated its classification of central nervous system tumors, adding 8 entities, as well as defining new variants and morphologic patterns of existing entities. Despite the continued refinement of brain tumor histologic classification and grading, there remain some diagnostic "gray zones" that challenge general surgical pathologists and neuropathologists alike. These include the presence of oligodendroglial features in (mixed) oligoastrocytomas and glioblastomas (GBMs), GBM variants (such as small cell GBM), meningioma classification and grading, medulloblastoma variants, ependymoma grading, the presence of "neuronal features" in otherwise morphologically classic gliomas, and low-grade gliomas with high Ki-67 labeling indices.
View Article and Find Full Text PDF